(CercleFinance.com) – Pharnext announced Tuesday its intention to convene its shareholders next month in order to provide itself with the legal and financial framework adapted to its partnership with Neovacs.
The biopharmaceutical company plans to hold a mixed general meeting (ordinary and extraordinary) on February 24 at the headquarters of Neovacs.
Its shareholders will in particular be called upon to decide on the implementation of a new legal structure with a transformation of the company, currently constituted as a public limited company, into a partnership limited by shares (SCA).
In terms of governance, Néovacs (represented by Hugo Brugière, CEO of Néovacs and current CEO of Pharnext) would become chairman of Pharnext Développement, which would itself in turn be manager of Pharnext.
The supervisory board of Pharnext, constituted as an SCA, would be made up of the current members of the board of directors, namely Joshua Schafer, Lawrence Steinman and James Kuo.